Glasses for Adolescent Delayed Sleep-Wake Phase Disorder (GLAD)

Overview

Información sobre este estudio

The purpose of this study is to determine if evening amber glasses combined with stable wake times will show an increase in total sleep time (TST), and an advance in sleep onset times (shift earlier) compared to the control group.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  1. Regular school attendance in the setting of a fixed start time.
  2. Adherence to ICSD‐3 DSWPD diagnostic criteria.
  3. Average spontaneous weekend wake time ≥1 hour than school day wake time.
  4. Initiation of school‐night sleep at 12 a.m. or later, ≥50% of the time, during a 14‐day period (items 3‐4 to be determined by sleep logs and actigraphy). As there are no discrete clock times associated with the ICSD‐3 DSWPD description, this cutoff is based on data obtained from the 2006 Sleep in America Poll and experiences gleaned from prior recruitment.

Exclusion Criteria:

  • A positive urine drug abuse screen will disqualify the individual from further participation.
  • Subjects will be withdrawn from the study if the sleep log and wrist monitor activity does not correspond with the sleep schedule identified with the pre-study sleep log.
  • Alcohol and nicotine use will also be screened to qualify for the study. We will also screen for alcohol immediately before each DLMO assessment because alcohol acutely suppresses melatonin.
  • Patients receiving medications that might contribute to sleep disturbances and/or affect treatment responses will be considered ineligible (e.g., hypnotics, antidepressants, stimulants, non‐steroidal anti‐inflammatory drugs (NSAIDs), beta blockers).
  • All subjects will be asked to refrain from caffeine use on the days of phase assessments, and to cease ingestion at least 6 hours prior to nightly bedtime.
  • The Ishihara Color Blindness Test will be done and patients who are color blind/deficient will be disqualified from participating in the study.

 

           

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

R Auger, M.D.

Cerrado para la inscripción

Contact information:

Deanna Hofschulte CCRP

(507) 255-2972

Hofschulte.Deanna@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20436936

Mayo Clinic Footer